Logo image of KRMD

KORU MEDICAL SYSTEMS INC (KRMD) Stock Fundamental Analysis

NASDAQ:KRMD - Nasdaq - US7599101026 - Common Stock - Currency: USD

3.25  +0.1 (+3.17%)

After market: 3.25 0 (0%)

Fundamental Rating

3

Overall KRMD gets a fundamental rating of 3 out of 10. We evaluated KRMD against 189 industry peers in the Health Care Equipment & Supplies industry. KRMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KRMD is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KRMD has reported negative net income.
KRMD had a negative operating cash flow in the past year.
In the past 5 years KRMD always reported negative net income.
KRMD had a negative operating cash flow in each of the past 5 years.
KRMD Yearly Net Income VS EBIT VS OCF VS FCFKRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

1.2 Ratios

The Return On Assets of KRMD (-22.29%) is comparable to the rest of the industry.
KRMD has a Return On Equity (-36.08%) which is in line with its industry peers.
Industry RankSector Rank
ROA -22.29%
ROE -36.08%
ROIC N/A
ROA(3y)-30.34%
ROA(5y)-21.02%
ROE(3y)-43.74%
ROE(5y)-29.41%
ROIC(3y)N/A
ROIC(5y)N/A
KRMD Yearly ROA, ROE, ROICKRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

KRMD has a better Gross Margin (63.40%) than 63.49% of its industry peers.
KRMD's Gross Margin has been stable in the last couple of years.
KRMD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.65%
GM growth 5Y-0.23%
KRMD Yearly Profit, Operating, Gross MarginsKRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

5

2. Health

2.1 Basic Checks

KRMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KRMD has been increased compared to 1 year ago.
Compared to 5 years ago, KRMD has more shares outstanding
The debt/assets ratio for KRMD has been reduced compared to a year ago.
KRMD Yearly Shares OutstandingKRMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
KRMD Yearly Total Debt VS Total AssetsKRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 7.71 indicates that KRMD is not in any danger for bankruptcy at the moment.
KRMD's Altman-Z score of 7.71 is amongst the best of the industry. KRMD outperforms 88.36% of its industry peers.
KRMD has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
KRMD's Debt to Equity ratio of 0.03 is fine compared to the rest of the industry. KRMD outperforms 65.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 7.71
ROIC/WACCN/A
WACC9.01%
KRMD Yearly LT Debt VS Equity VS FCFKRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

KRMD has a Current Ratio of 2.66. This indicates that KRMD is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.66, KRMD perfoms like the industry average, outperforming 50.79% of the companies in the same industry.
A Quick Ratio of 2.27 indicates that KRMD has no problem at all paying its short term obligations.
The Quick ratio of KRMD (2.27) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 2.27
KRMD Yearly Current Assets VS Current LiabilitesKRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

KRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.38%, which is quite good.
KRMD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.98%.
KRMD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.76% yearly.
EPS 1Y (TTM)15.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)17.98%
Revenue growth 3Y12.72%
Revenue growth 5Y7.76%
Sales Q2Q%17.59%

3.2 Future

KRMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.04% yearly.
The Revenue is expected to grow by 16.49% on average over the next years. This is quite good.
EPS Next Y-0.57%
EPS Next 2Y26.98%
EPS Next 3Y34.04%
EPS Next 5YN/A
Revenue Next Year15.67%
Revenue Next 2Y15.14%
Revenue Next 3Y16.49%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
KRMD Yearly Revenue VS EstimatesKRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M 50M
KRMD Yearly EPS VS EstimatesKRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.05 -0.1 -0.15 -0.2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

KRMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KRMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KRMD Price Earnings VS Forward Price EarningsKRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60 -80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KRMD Per share dataKRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

KRMD's earnings are expected to grow with 34.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.98%
EPS Next 3Y34.04%

More info and screens

0

5. Dividend

5.1 Amount

KRMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KORU MEDICAL SYSTEMS INC

NASDAQ:KRMD (5/12/2025, 4:05:07 PM)

After market: 3.25 0 (0%)

3.25

+0.1 (+3.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)N/A N/A
Inst Owners51.03%
Inst Owner ChangeN/A
Ins Owners6.35%
Ins Owner Change8.46%
Market Cap147.52M
Analysts80
Price Target5.81 (78.77%)
Short Float %1.23%
Short Ratio3.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.24%
Min EPS beat(2)3.88%
Max EPS beat(2)22.6%
EPS beat(4)4
Avg EPS beat(4)32.05%
Min EPS beat(4)3.88%
Max EPS beat(4)53.31%
EPS beat(8)8
Avg EPS beat(8)26.41%
EPS beat(12)11
Avg EPS beat(12)23.76%
EPS beat(16)13
Avg EPS beat(16)-2.86%
Revenue beat(2)1
Avg Revenue beat(2)0.92%
Min Revenue beat(2)-2.56%
Max Revenue beat(2)4.4%
Revenue beat(4)3
Avg Revenue beat(4)4.67%
Min Revenue beat(4)-2.56%
Max Revenue beat(4)9.18%
Revenue beat(8)4
Avg Revenue beat(8)-0.22%
Revenue beat(12)7
Avg Revenue beat(12)0.92%
Revenue beat(16)11
Avg Revenue beat(16)2.11%
PT rev (1m)0%
PT rev (3m)3.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.79%
Revenue NY rev (1m)1.43%
Revenue NY rev (3m)1.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.38
P/FCF N/A
P/OCF N/A
P/B 8.77
P/tB 9.17
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.74
BVpS0.37
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.29%
ROE -36.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.4%
FCFM N/A
ROA(3y)-30.34%
ROA(5y)-21.02%
ROE(3y)-43.74%
ROE(5y)-29.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.65%
GM growth 5Y-0.23%
F-Score5
Asset Turnover1.24
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 150.99%
Cap/Sales 3.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 2.27
Altman-Z 7.71
F-Score5
WACC9.01%
ROIC/WACCN/A
Cap/Depr(3y)239.72%
Cap/Depr(5y)210.83%
Cap/Sales(3y)5.63%
Cap/Sales(5y)4.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y-0.57%
EPS Next 2Y26.98%
EPS Next 3Y34.04%
EPS Next 5YN/A
Revenue 1Y (TTM)17.98%
Revenue growth 3Y12.72%
Revenue growth 5Y7.76%
Sales Q2Q%17.59%
Revenue Next Year15.67%
Revenue Next 2Y15.14%
Revenue Next 3Y16.49%
Revenue Next 5YN/A
EBIT growth 1Y37.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year83.98%
EBIT Next 3Y46.94%
EBIT Next 5YN/A
FCF growth 1Y70.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y93.47%
OCF growth 3YN/A
OCF growth 5YN/A